Seattle Genetics Inc. (SGEN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Seattle Genetics ( SGEN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Seattle Genetics rose $0.46 (1.1%) to $42.65 on average volume. Throughout the day, 1,082,012 shares of Seattle Genetics exchanged hands as compared to its average daily volume of 821,300 shares. The stock ranged in a price between $41.87-$42.73 after having opened the day at $42.03 as compared to the previous trading day's close of $42.19. Other companies within the Drugs industry that increased today were: OncoMed Pharmaceuticals ( OMED), up 97.9%, Conatus Pharmaceuticals ( CNAT), up 18.1%, Galectin Therapeutics ( GALT), up 13.2% and Prima Biomed ( PBMD), up 11.8%.

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Seattle Genetics has a market cap of $5.0 billion and is part of the health care sector. Shares are up 82.1% year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Seattle Genetics a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share.

On the negative front, Mast Therapeutics ( MSTX), down 39.4%, Echo Therapeutics ( ECTE), down 17.2%, PDL BioPharma ( PDLI), down 11.2% and Biostar Pharmaceuticals ( BSPM), down 8.8% , were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists